cytosine has been researched along with Virus Diseases in 16 studies
Virus Diseases: A general term for diseases caused by viruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nature 1986;323:464-7], the acyclic nucleoside phosphonates have acquired a prominent therapeutic position: (i) cidofovir in the treatment of papilloma-, herpes-, adeno- and poxvirus infections, (ii) adefovir in the treatment of chronic hepatitis B virus (HBV) infections, and (iii) tenofovir in the treatment of human immunodeficiency virus (HIV) infections (AIDS)." | 3.74 | Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. ( De Clercq, E, 2007) |
| "Ribavirin has also been used to treat parainfluenza virus and human metapneumovirus, but data are inconclusive in this setting." | 2.53 | Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology. ( Berger, A; Christopeit, M; Hauf, E; Hentrich, M; Heussel, CP; Kalkreuth, J; Klein, M; Kochanek, M; Lehners, N; Mayer, K; Penack, O; Rieger, C; Schalk, E; Silling, G; Vehreschild, M; von Lilienfeld-Toal, M; Weber, T; Wolf, HH, 2016) |
| " In paediatric patients this may be difficult to achieve due to lack of pharmacokinetic studies, administration of small doses, changes in body composition, continuous growth, and development and maturation of organs and systems." | 2.42 | The pharmacokinetics of antiviral therapy in paediatric patients. ( Eksborg, S, 2003) |
| "Several new agents for treating viral infections have been developed in recent years." | 2.40 | Antiviral agents for non-human immunodeficiency virus infections. ( Keating, MR, 1999) |
| " HPMPC confers a prolonged antiviral action, which lasts for several days or weeks, thus allowing infrequent dosing (i." | 1.29 | Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. ( De Clercq, E, 1996) |
| " Concentrations of cidofovir in kidney declined with a half-life of 23 hr and were > 1,000-fold higher than plasma levels by 120 hr." | 1.29 | Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. ( Cundy, KC; Hitchcock, MJ; Lee, WA; Li, ZH, 1996) |
| " The corrected half-life of cyclic HPMPC was 0." | 1.29 | Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. ( Bidgood, AM; Cundy, KC; Griffin, L; Lee, WA; Lynch, G; Shaw, JP, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brisse, E | 1 |
| Imbrechts, M | 1 |
| Mitera, T | 1 |
| Vandenhaute, J | 1 |
| Wouters, CH | 1 |
| Snoeck, R | 1 |
| Andrei, G | 1 |
| Matthys, P | 1 |
| De Clercq, E | 5 |
| von Lilienfeld-Toal, M | 1 |
| Berger, A | 1 |
| Christopeit, M | 1 |
| Hentrich, M | 1 |
| Heussel, CP | 1 |
| Kalkreuth, J | 1 |
| Klein, M | 1 |
| Kochanek, M | 1 |
| Penack, O | 1 |
| Hauf, E | 1 |
| Rieger, C | 1 |
| Silling, G | 1 |
| Vehreschild, M | 1 |
| Weber, T | 1 |
| Wolf, HH | 1 |
| Lehners, N | 1 |
| Schalk, E | 1 |
| Mayer, K | 1 |
| Krecmerová, M | 1 |
| Masojídková, M | 1 |
| Holý, A | 1 |
| Eksborg, S | 1 |
| Stringfellow, DA | 1 |
| Fernández-Puentes, C | 1 |
| Cundy, KC | 2 |
| Li, ZH | 1 |
| Hitchcock, MJ | 1 |
| Lee, WA | 2 |
| Bidgood, AM | 1 |
| Lynch, G | 1 |
| Shaw, JP | 1 |
| Griffin, L | 1 |
| Keating, MR | 1 |
| Kohlschütter, A | 1 |
| Pelet, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression[NCT01387022] | 59 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference between 12 months and randomisation CD4+ count was calculated and then summarised (NCT01387022)
Timeframe: Measured at 12 months post ART initiation
| Intervention | cells/uL (Median) |
|---|---|
| Tenofovir-containing Regimen | 217 |
| Tenofovir-sparing Regimen | 174 |
(NCT01387022)
Timeframe: From randomisation until either time of termination or time of death
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir-containing Regimen | 7 |
| Tenofovir-sparing Regimen | 12 |
(NCT01387022)
Timeframe: From randomisation until either time of termination or time of death
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenofovir-containing Regimen | 1 |
| Tenofovir-sparing Regimen | 1 |
Treatment failure is defined as viral load > 50 copies/ml, antiretroviral regimen changes for treatment failure or death (NCT01387022)
Timeframe: 12 months post ART intiation or until time of death
| Intervention | participants (Number) |
|---|---|
| Tenofovir-containing Regimen | 4 |
| Tenofovir-sparing Regimen | 5 |
6 reviews available for cytosine and Virus Diseases
| Article | Year |
|---|---|
The Holý Trinity: the acyclic nucleoside phosphonates.
Topics: Adenine; Antiviral Agents; Cidofovir; Cytosine; Drug Therapy, Combination; Humans; Nucleosides; Orga | 2013 |
Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.
Topics: Adenovirus Infections, Human; Antiviral Agents; Cidofovir; Community-Acquired Infections; Cytosine; | 2016 |
The pharmacokinetics of antiviral therapy in paediatric patients.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Child; Child, Hospitalized; Cidofovir; Cytosine; Famcicl | 2003 |
The discovery of antiviral agents: ten different compounds, ten different stories.
Topics: Acyclovir; Adenine; Antiviral Agents; Benzodiazepines; Benzylamines; Cidofovir; Cyclams; Cytosine; H | 2008 |
Antiviral agents for non-human immunodeficiency virus infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cytosine; Drug Resist | 1999 |
Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; HIV Infections; Humans; Organophosphonates; | 1990 |
10 other studies available for cytosine and Virus Diseases
| Article | Year |
|---|---|
Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis.
Topics: Animals; Antiviral Agents; Cidofovir; Cytosine; Dexamethasone; Disease Models, Animal; Humans; Immun | 2017 |
Acyclic nucleoside phosphonates with 5-azacytosine base moiety substituted in C-6 position.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cytosine; Humans; Nucleosides; Organopho | 2010 |
Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Hepacivirus; Hepatitis B virus; HIV; Humans | 2007 |
Antineoplastic properties of pyrimidinone interferon inducers.
Topics: Animals; Cytosine; Female; Immunity; Interferon Inducers; Interferons; Melanoma; Mice; Mice, Inbred | 1980 |
Permeability to inhibitors of protein synthesis in virus infected cells.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Cell Membrane Permeability; Cells, Cultured; Cricet | 1984 |
Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
Topics: Animals; Antiviral Agents; Base Sequence; Cattle; Cidofovir; Clinical Trials as Topic; Cytosine; DNA | 1996 |
Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antiviral Agents; Biological Availability; | 1996 |
Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats.
Topics: Administration, Cutaneous; Animals; Antiviral Agents; Biological Availability; Carbon Radioisotopes; | 1996 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Amantadine; Antiviral Agents; Cidofovir; Cont | 1997 |
Pulmonary candidiasis treated with 5-fluorocytosine.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Child; Cytosine; Female; Flucytosine; Humans; Immu | 1974 |